May 2023 Top Biopharma Deal Upfront
May 3, 2023
$245M + Milestones
$245M
n/a
n/a
Undisclosed dev., reg., and sales milestones
Undisclosed
n/a
Preclinical C-CAR039, an anti-CD19 & CD20 bi-specific CAR-T therapy, and C-CAR066, an anti-CD20 CAR-T for the treatment of Non-Hodgkin Lymphoma (NHL)
Dev and Commercial License
Collaborative Development, No Shared Cost , Options to Add Products, TAs, and/or Territories , Supply by Licensor
Congrats to Cellular Biomedicine and Janssen for landing DealForma’s May 2023 Top Biopharma Deal. Last month’s Deal of the Month was DualityBio – BioNTech for DB-1303 and DB-1311. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personlized demo.
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive